RE:RE:RE:RE:AnywaysI think that there's a lot of really good points here. I think the main ones are expertise in plant to pain med, global supply chain, cost effective place to produce, and full (and only) license in Spain (bringing their licenses in Europe to two - Denmark & Spain & Germany on the horizon). Playing devils advocate, some are suggesting that Canopy may be taking it's eye off the price - legal REC in Canada. I don't agree as I think that there's good overlap between the two organizations & Canopy could greatly benefit from Alcaliber IP. Anyone have any thoughts as to the potential downsides to this deal??